PXS-4728 by Syntara for Sleep Disorders: Likelihood of Approval

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Physician’s Contract Ordeal Reveals Flaws in Corporate Practice of Medicine Laws

Rheumatologist Jason Liebowitz, MD, was “really enjoying” his job at a physician-owned practice when, about a year in, it was acquired by a private equity

June 5, 2024

Under pressure to thwart pharma patent abuse, the PTO proposes a new rule. But will it fly?

In a bid to prevent the patent system from being abused, the U.S. Patent and Trademark Office has proposed a new rule designed to stem

June 17, 2024

3 CRISPR advances to watch in 2024

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing

December 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.